Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic vs reference galantamine prolonged-release capsules in healthy Thai adults under fed conditions
TCTR20260813012Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of galantamine in Alzheimer's disease (AD) (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration-time curve to last observed concentration and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on TCTR20260813012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260813012.